AND ‐1 Enhances Erastin‐Induced Ferroptosis in Ovarian Cancer Cells by Down‐Regulating SLC7A11 and NRF2
BioFactors · 2026-05 · 52 (3)
DOI: 10.1002/biof.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, online erschienen am 31.05.2026. Verfasst von Jingjing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine,…. Hauptthemen laut MEDLINE: Ferroptosis, Piperazines, NF-E2-Related Factor 2, Amino Acid Transport System y+. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Ferroptosis is a highly synchronized form of non‐apoptotic intracellular iron‐dependent cell death which is regulated by multiple cellular metabolic pathways. Extensive studies suggest that ferroptosis could efficiently set the therapy resistant cancer cells on the road to ruin, thus providing new opportunities for cancer therapy. And‐1 is an acidic nucleoplasmic DNA binding protein which plays a vital role in DNA replication and repair. Here in this study, we report a novel function of And‐1 in regulating erastin‐induced ferroptosis in ovarian cancer cells. And‐1 overexpression (OE) enhanced erastin‐induced ferroptosis by modulating the level of ferroptosis biomarkers such as MDA, GSH, Fe 2+ and lipid peroxidation; while knockdown (KD) of And‐1 produces opposite results. Moreover And‐1(OE) suppressed the expression of NRF2, SLC7A11, and FTH1 and promoted the expression of TFR1 and ATF3 while And‐1 (KD) produces opposite results. Further mechanistic study revealed that And‐1 inhibits the expression of SLC7A11 by increasing ATF3 expression. Moreover, using pharmacological inhibitors, we have shown that erastin induces ferroptosis through multiple mechanisms. Taken together, our data suggest that And‐1 enhanced erastin‐induced ferroptosis in OC cells by inhibiting system x c − expression through ATF3 and suppressing NRF2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Cancer Research Lab, Institute of Zoology, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan.
- Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Xiao Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Li, J., Li, L., Xia, X., Khan, M., Zhang, Y., Zhang, Y., Wu, X., Ma, T., & Li, Y. (2026). AND ‐1 Enhances Erastin‐Induced Ferroptosis in Ovarian Cancer Cells by Down‐Regulating SLC7A11 and NRF2. BioFactors, 52(3). https://doi.org/10.1002/biof.70117
Vancouver
Li J, Li L, Xia X, Khan M, Zhang Y, Zhang Y, et al. AND ‐1 Enhances Erastin‐Induced Ferroptosis in Ovarian Cancer Cells by Down‐Regulating SLC7A11 and NRF2. BioFactors. 2026;52(3). doi:10.1002/biof.70117
BibTeX
@article{Li2026,
author = {Li, Jingjing and Li, Lingyan and Xia, Xinye and Khan, Muhammad and Zhang, Yaqi and Zhang, Yingwei and Wu, Xiao and Ma, Tonghui and Li, Yongming},
title = {AND ‐1 Enhances Erastin‐Induced Ferroptosis in Ovarian Cancer Cells by Down‐Regulating SLC7A11 and NRF2},
journal = {BioFactors},
year = {2026},
volume = {52},
number = {3},
doi = {10.1002/biof.70117}
}
EUVIMED